20-F: InterCure 2025 Annual Report: Recovery and Growth
Annual Report
InterCure reports 2025 financial results, highlighting recovery efforts at its Southern Facility and continued expansion.
Summary
- Consolidated revenue for 2025 reached NIS 270 million, a 13% increase over 2024.
- Consolidated net loss narrowed to NIS 37 million in 2025 from NIS 73 million in 2024.
- Adjusted EBITDA for 2025 was NIS 42 million, marking the sixth consecutive year of positive Adjusted EBITDA.
- The company achieved positive cash flow from operations of NIS 17 million in 2025, compared to negative cash flow of NIS 67 million in 2024.
- The company received NIS 82 million in advance compensation from Israeli authorities for war-related damages to its Southern Facility.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral sentiment, reflecting a company in a stabilization and recovery phase, balancing operational growth against significant geopolitical and regulatory risks.
Positives
- Revenue growth of 13% year-over-year.
- Sixth consecutive year of positive Adjusted EBITDA.
- Turnaround to positive operating cash flow of NIS 17 million.
- Successful completion of NIS 66 million financing in early 2025.
- Resumption of production and sales from the Southern Facility following war-related disruptions.
Negatives
- Continued net loss of NIS 37 million.
- Significant ongoing impact from war-related damages and operational disruptions in Israel.
- High volatility in the cannabis industry and regulatory uncertainty.
- Ongoing legal disputes with former business partners.
Risks
- Geopolitical instability and armed conflicts in the Middle East affecting operations.
- Dependence on regulatory approvals and licenses for cannabis production and distribution.
- Potential for further crop failure or security breaches at facilities.
- Risk of delisting from Nasdaq due to minimum bid price requirements.
- Exposure to currency fluctuations and inflationary pressures.
Future Outlook
The company aims to be a global leader in pharmaceutical-grade cannabis, focusing on expansion in Israel, the EU, and Australia, while continuing the restoration and capacity expansion of its Southern Facility.
Management Comments
- Management is working diligently with Israeli authorities to obtain full compensation for war-related damages.
- The company remains focused on operational excellence and expanding its global footprint.
Industry Context
StockSavvy.ai notes that the medical cannabis industry remains highly sensitive to regulatory shifts and geopolitical stability, with InterCure's performance heavily tied to the recovery of its Israeli operations and the evolving European regulatory landscape.
Comparison to Industry Standards
- Performance is consistent with other mid-cap cannabis operators facing regional geopolitical headwinds.
- The company's focus on GMP-certified pharmaceutical-grade products aligns with global industry standards for medical cannabis.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Chairman of the Board | Ehud Barak | Alexander Rabinovich | 2025-02-13 | Ehud Barak stepped down. |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Clawback Policy | Adoption of a policy to recover incentive-based compensation in the event of financial restatements. | 2024-11-01 | Enhances corporate governance and alignment with regulatory requirements. |
Legal Proceedings
- Ongoing litigation with Cann Pharmaceutical Ltd. regarding breach of contract and counterclaim.
- Ongoing litigation with Geffen Residence & Renewal Ltd. regarding purchase agreement breach.
- Class action lawsuit regarding medical cannabis advertising (dismissed in 2026).
- Proof of claim filed against Bazelet group in restructuring proceedings.
Related Party Transactions
- Bridge loan provided by controlling shareholder Alexander Rabinovich.
- Sublease agreements with companies related to Alexander Rabinovich.
Stakeholder Impact
- Shareholders face potential dilution from future warrant exercises and share issuances.
- Employees and local communities in Israel are impacted by the company's ongoing recovery and facility restoration efforts.
Next Steps
- Continue restoration and expansion of the Southern Facility.
- Evaluate the future of the clinical trial program.
- Monitor and manage legal disputes with former partners.
- Pursue further international expansion in Germany and other EU markets.
Key Dates
| Date | Description |
|---|---|
| 2025-01-29 | Completion of Leon Pharm acquisition. |
| 2025-02-12 | Announcement of leadership change and financing completion. |
| 2025-03-03 | Closing of private placement offering. |
| 2025-12-31 | Fiscal year end. |
Recommendation
holdThe stock is a hold due to the company's successful operational recovery and revenue growth, which are currently offset by significant geopolitical risks, ongoing legal disputes, and the speculative nature of its international expansion plans.
Keywords
medical cannabis, InterCure, INCR, pharmaceutical-grade cannabis, Israel medical cannabis, cannabis regulation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.